Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published in the Journal of the American Heart Association. This research was presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans.

AI summaries can be wrong sometimes—always verify important details using the source article.